CRB’s Horizons: Life Sciences 2026 report finds that life sciences companies are expanding manufacturing capacity and investing in advanced therapies, AI and automation despite rising costs and regulatory challenges. Based on a survey of more than 400 industry leaders, the report highlights growing demand for skilled workers, the importance of established biopharmaceutical hubs, and increased manufacturing interest across all surveyed drug modalities.
